2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0389R
    D-Glucose (Standard) 50-99-7 99.83%
    D-Glucose (Standard) is the analytical standard of D-Glucose. This product is intended for research and analytical applications. D-Glucose is the naturally occurring form of glucose and the most abundant monosaccharide. D-Glucose is a critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic or abiotic stress response.
    D-Glucose (Standard)
  • HY-N1214R
    Squalene (Standard) 111-02-4
    Squalene (Standard) is the analytical standard of Squalene. This product is intended for research and analytical applications. Squalene (Super Squalene) is an intermediate product in the synthesis of cholesterol, and shows several pharmacological properties such as hypolipidemic, hepatoprotective, antiatherosclerotic, cardioprotective, antioxidant, and antitumour activity.
    Squalene (Standard)
  • HY-U00205
    Dopexamine hydrochloride 86484-91-5 98.04%
    Dopexamine hydrochloride is a β2 adrenergic receptor agonist.
    Dopexamine hydrochloride
  • HY-141749B
    Clopidogrel carboxylic acid hydrochloride 144750-42-5 99.66%
    Clopidogrel carboxylic acid (CLPM) hydrochloride is an inactive metabolite of the widely used antiplatelet medication clopidogrel, which serves as a reference standard for quantitative analysis of clopidogrel metabolism. Clopidogrel carboxylic acid hydrochloride has been shown to represent approximately 85% of circulating clopidogrel, hydrolyzed from the active form by esterases. Clopidogrel carboxylic acid hydrochloride plays a crucial role in assessing the pharmacokinetics and bioavailability of clopidogrel in various clinical and research settings.
    Clopidogrel carboxylic acid hydrochloride
  • HY-W010451
    1,2,4-Trihydroxybenzene 533-73-3 ≥98.0%
    1,2,4-Trihydroxybenzene (Hydroxyhydroquinone) is an ER stress inducer that targets proteins such as PKR-like ER kinase PERK to induce cytotoxicity. 1,2,4-Trihydroxybenzene selectively activates eIF2α phosphorylation, activates the PERK-eIF2α signaling pathway and induces stress granule formation. 1,2,4-Trihydroxybenzene subsequently exacerbates oxidative stress and causes DNA double-strand breaks, destroying organelles such as mitochondria and ER, and inducing cell death. 1,2,4-Trihydroxybenzene also has the potential to exhibit anti-tumor effect, increase blood pressure, and relieve spasm.
    1,2,4-Trihydroxybenzene
  • HY-W015820
    Phthalide 87-41-2 99.94%
    Phthalide is a chemical scaffold. Phthalide can be used to synthesize a variety of phthalide derivatives including anti-inflammatory agent, antimicrobial, antioxidant and blood-tumor barrier modulators.
    Phthalide
  • HY-109037S3
    Mavacamten-d5 2453251-00-6 98.61%
    Mavacamten-d5 (MYK461-d5; SAR439152-d5) is deuterium labeled Mavacamten (HY-109037). Mavacamten (MYK461) is an orally active modulator of cardiac myosin, with IC50s of 490, 711 nM for bovine cardiac and human cardiac, respectively.
    Mavacamten-d5
  • HY-N0830S10
    Palmitic acid-13C2 86683-25-2 99.54%
    Palmitic acid-13C2 is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-13C2
  • HY-120343
    GSK106 1652591-82-6 98.28%
    GSK106 is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199.
    GSK106
  • HY-15472
    PRX-08066 866206-54-4
    PRX-08066 is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 inhibits pulmonary vascular remodeling. PRX-08066 can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET).
    PRX-08066
  • HY-B0523
    Anagrelide 68475-42-3 99.87%
    Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action.
    Anagrelide
  • HY-106004
    Zamicastat 1080028-80-3 99.93%
    Zamicastat (BIA 5-1058) is a dopamine β-hydroxylase (DBH) inhibitor and can cross the blood-brain barrier (BBB) to cause central as well as peripheral effects. Zamicastat is also a concentration-dependent dual P-gp and BCRP inhibitor with IC50 values of 73.8 μM and 17.0 μM, respectively. Zamicastat reduces high blood pressure.
    Zamicastat
  • HY-124063
    BI-1935 940954-41-6 98.01%
    BI-1935, a chemical probe, is a potent soluble epoxide hydrolase (sEH) inhibitor. BI-1935 can be used for the research of cardiovascular disease.
    BI-1935
  • HY-A0064S
    Verapamil-d3 hydrochloride 2714485-49-9 99.57%
    Verapamil-d3 (hydrochloride) is the deuterium labeled Verapamil hydrochloride. Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research.
    Verapamil-d3 hydrochloride
  • HY-B0578A
    Loxoprofen sodium 80382-23-6 99.63%
    Loxoprofen sodium is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen sodium can reduce atherosclerosis and shows antitumor activity.
    Loxoprofen sodium
  • HY-B0185AS
    Lidocaine-d10 hydrochloride 1189959-13-4 99.55%
    Lidocaine-d10 (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia.
    Lidocaine-d10 hydrochloride
  • HY-10678
    BMS-687453 1000998-59-3 99.31%
    BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
    BMS-687453
  • HY-44809
    Izilendustat 1303512-02-8
    Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1).
    Izilendustat
  • HY-N0401
    Ligustilide 4431-01-0 99.17%
    Ligustilide is is a bioactive phthalide derivative isolated from Angelica sinensis and Chuanxiong. Ligustilide exhibits neuroprotective, anti-cancer, anti-inflammatory, and vasodilator effects.
    Ligustilide
  • HY-109002
    Apararenone 945966-46-1 99.09%
    Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.
    Apararenone
Cat. No. Product Name / Synonyms Application Reactivity